Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05953610 · ClinicalTrials.gov registry record · Phase 2
Endotypic Traits and Obstructive Sleep Apnea Surgery
A Phase 2 study of Obstructive Sleep Apnea, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 2
- Study locations
NCT05953610: Recruiting Phase 2 study of Obstructive Sleep Apnea, sponsored by University of California, Los Angeles.
NCT05953610 is a Phase 2 study of Obstructive Sleep Apnea that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 150 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (32% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05953610, a Phase 2 study of Obstructive Sleep Apnea, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).
Primary Outcome
apneas plus hypopneas per hour of sleep
Conditions Studied
Interventions
- DRUG Acetazolamide 500 MG QHS
- DRUG Eszopiclone 3 mg QHS
Study Locations (2)
California
- UCLA Santa Monica Medical Center - Santa Monica
- UCLA Westwood - Westwood, Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-01-07 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 2 |
What NCT05953610 shows while recruiting
NCT05953610 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (32% lower).
The record links to 1 condition, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 2 interventions - of which Acetazolamide 500 MG QHS is the first listed.
NCT05953610 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05953610 about?
NCT05953610 is a clinical study titled "Endotypic Traits and Obstructive Sleep Apnea Surgery". This study will examine factors associated with outcomes after soft palate surgery and medications (acetazolamide, eszopiclone) that may treat other potential causes of obstructive sleep apnea (loop gain, arousal threshold).
What is the current status of trial NCT05953610?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-01-07. Estimated completion is 2028-08-31.
What conditions does trial NCT05953610 study?
This clinical trial studies the following conditions: Obstructive Sleep Apnea.
What interventions are being tested in trial NCT05953610?
The interventions under investigation include: Acetazolamide 500 MG QHS (DRUG), Eszopiclone 3 mg QHS (DRUG).
Who is sponsoring clinical trial NCT05953610?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05953610 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Sleep Apnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05953610's enrollment target sits among peer trials
150 47th of 155 higher than 108 of 155 other Obstructive Sleep Apnea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obstructive Sleep Apnea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient-centered and Neurocognitive Outcomes with Acetazolamide for Sleep Apnea
RECRUITING · Phase 2
-
The Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome)
RECRUITING · Phase 2
-
Do Endotypes Predict Response and Sequelae in OSA Patients
RECRUITING · Phase 2
-
Medications for Obstructive Sleep Apnea to Improve Cognition in Children With Down Syndrome
RECRUITING · Phase 2
-
Down Syndrome Obstructive Sleep Apnea
RECRUITING · Phase 2
-
Dexmedetomidine Versus Propofol Sedation for Drug-Induced Sleep Endoscopy in Pediatric Obstructive Sleep Apnea
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI